Fasinumab (Anti-Human NGF), a human IgG1κ monoclonal antibody targeting nerve growth factor (NGF), can be used in studies about acute sciatica and knee osteoarthritis (OA). clinical research has demonstrated that Fasinumab achieves statistically significant improvements in both pain and physical function scores when compared to a placebo control group.